Pacific Biosciences Of California (PACB) Profit After Tax Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.60% |
| Dec 31, 2025 | -20.48% |
| Sep 30, 2025 | -9.89% |
| Jun 30, 2025 | -12.68% |
| Mar 31, 2025 | -220.77% |
| Dec 31, 2024 | 94.81% |
| Sep 30, 2024 | -15.83% |
| Jun 30, 2024 | -47.77% |
| Mar 31, 2024 | -20.85% |
| Dec 31, 2023 | -21.64% |
| Sep 30, 2023 | -21.70% |
| Jun 30, 2023 | -25.38% |
| Mar 31, 2023 | -29.49% |
| Dec 31, 2022 | -32.37% |
| Sep 30, 2022 | -28.44% |
| Jun 30, 2022 | -22.83% |
| Mar 31, 2022 | -27.84% |
| Dec 31, 2021 | -29.51% |
| Jun 30, 2021 | -17.25% |
| Mar 31, 2021 | -35.20% |
| Dec 31, 2020 | 123.03% |
| Sep 30, 2020 | -71.92% |
| Jun 30, 2020 | -14.11% |
| Mar 31, 2020 | 15.58% |
| Dec 31, 2019 | 65.63% |
| Sep 30, 2019 | -26.02% |
| Jun 30, 2019 | -5.15% |
| Mar 31, 2019 | -9.93% |
| Dec 31, 2018 | -12.32% |
| Sep 30, 2018 | -4.10% |
| Jun 30, 2018 | -1.94% |
| Mar 31, 2018 | -2.76% |
| Dec 31, 2017 | 0.85% |
| Sep 30, 2017 | 0.63% |
| Jun 30, 2017 | -2.58% |
| Mar 31, 2017 | 2.85% |
| Dec 31, 2016 | 3.57% |
| Sep 30, 2016 | 9.79% |
| Jun 30, 2016 | 3.98% |
| Mar 31, 2016 | 11.08% |
| Dec 31, 2015 | 47.85% |
| Sep 30, 2015 | 15.38% |
| Jun 30, 2015 | 18.26% |